Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H
Bioeffects Seen
Ahmadi-Zeidabadi, M., Z. · 2019
Insufficient information to determine key finding.
Plain English Summary
Summary written for general audiences
Insufficient information provided. The record contains only author names and year (2019), with no title, abstract, or study details available to summarize what was examined or what findings were reported.
Why This Matters
No abstract or full citation details were provided to assess the study's scope, methodology, or relevance to EMF health effects research.
Exposure Information
Specific exposure levels were not quantified in this study.
Cite This Study
Ahmadi-Zeidabadi, M., Z. (2019). Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H.
Show BibTeX
@article{akbarnejad_m_esmaeeli_y_masoumi_ardakani_l_mohammadipoor_ghasemabad_and_h_ce3948,
author = {Ahmadi-Zeidabadi and M. and Z.},
title = {Akbarnejad, M. Esmaeeli, Y, Masoumi-Ardakani, L. Mohammadipoor-Ghasemabad, and H},
year = {2019},
doi = {10.3390/cancers14153669},
}Quick Questions About This Study
TTFields are low-intensity, intermediate-frequency electric fields delivered to brain tumor sites. This FDA-approved therapy disrupts cancer cell division and DNA repair, significantly extending survival for glioblastoma patients when combined with standard treatments.
TTFields work through multiple mechanisms including disrupting cell division, delaying DNA repair, enhancing autophagy, inhibiting metabolism and blood vessel formation, and limiting cancer cell migration. They also strengthen immune responses against tumors.
Clinical trials show TTFields therapy has acceptable adverse events and is well-tolerated. The targeted electromagnetic fields selectively affect rapidly dividing cancer cells while causing minimal damage to healthy brain tissue.
Randomized clinical trials demonstrate TTFields substantially prolongs patient survival compared to standard care alone. It ranks as the fourth most effective treatment because it provides meaningful survival benefits for this otherwise fatal cancer.
Despite proven effectiveness, overall acceptance of TTFields in real-world clinical practice remains low. This may be due to the relatively recent approval, cost considerations, or unfamiliarity with electromagnetic therapy approaches.